Multiplex proteomics identifies inflammation-related plasma biomarkers for aging and cardio-metabolic disorders
ConclusionOur results could reveal molecular markers for normal aging and CMDs, which need to be further expanded the sample size and to be further investigated to predict their significance for CVDs. (Source: Clinical Proteomics)
Source: Clinical Proteomics - April 22, 2024 Category: Biochemistry Source Type: research
Proteomics study of primary and recurrent adamantinomatous craniopharyngiomas
ConclusionsThis study provides a preliminary description of the proteomic differences between primary ACP, recurrent ACP, and RCC. Our findings serve as a resource for craniopharyngioma researchers and may ultimately expand existing knowledge of recurrent ACP and benefit clinical practice. (Source: Clinical Proteomics)
Source: Clinical Proteomics - April 9, 2024 Category: Biochemistry Source Type: research
The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies
ConclusionThe 3 markers can univariately and multivariately classify with moderate accuracy the samples with seropositivity and seronegativity for αAQP4 and αMOG. (Source: Clinical Proteomics)
Source: Clinical Proteomics - April 5, 2024 Category: Biochemistry Source Type: research
Plasma proteomic characterization of colorectal cancer patients with FOLFOX chemotherapy by integrated proteomics technology
ConclusionsOur study sheds light on the pathways affected in CRC patients treated with FOLFOX chemotherapy and identifies potential biomarkers that could be valuable for prognosis prediction. Our findings showed the potential of mass spectrometry-based proteomics and machine learning as an unbiased and systematic approach for discovering biomarkers in CRC. (Source: Clinical Proteomics)
Source: Clinical Proteomics - April 5, 2024 Category: Biochemistry Source Type: research
Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
ConclusionsCombining PRM and DIA measurements provides a new strategy for the sensitive and reproducible detection of protein markers from patients currently being discussed in molecular tumor boards in combination with the opportunity to discover new biomarker candidates. (Source: Clinical Proteomics)
Source: Clinical Proteomics - April 2, 2024 Category: Biochemistry Source Type: research
Correction: Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry
(Source: Clinical Proteomics)
Source: Clinical Proteomics - March 28, 2024 Category: Biochemistry Source Type: research
Quantitative proteomic analysis of HER2 protein expression in PDAC tumors
AbstractMetastatic pancreatic adenocarcinoma (PDAC) is the third leading cause of cancer-related death in the United States, with a 5-year survival rate of only 11%, necessitating identification of novel treatment paradigms. Tumor tissue specimens from patients with PDAC, breast cancer, and other solid tumor malignancies were collected and tumor cells were enriched using laser microdissection (LMD). Reverse phase protein array (RPPA) analysis was performed on enriched tumor cell lysates to quantify a 32-protein/phosphoprotein biomarker panel comprising known anticancer drug targets and/or cancer-related total and phosphory...
Source: Clinical Proteomics - March 20, 2024 Category: Biochemistry Source Type: research
Human tear film protein sampling using soft contact lenses
ConclusionsThese experiments demonstrate that SCLs are an accessible tear-sampling method with the potential to surpass current methods in sampling basal tears.Graphical Abstract (Source: Clinical Proteomics)
Source: Clinical Proteomics - March 13, 2024 Category: Biochemistry Source Type: research
Proteomics of prostate cancer serum and plasma using low and high throughput approaches
AbstractDespite progress, MS-based proteomics in biofluids, especially blood, faces challenges such as dynamic range and throughput limitations in biomarker and disease studies. In this work, we used cutting-edge proteomics technologies to construct label-based and label-free workflows, capable of quantifying approximately 2,000 proteins in biofluids. With 70 µL of blood and a single depletion strategy, we conducted an analysis of a homogenous cohort (n = 32), comparing medium-grade prostate cancer patients (Gleason score: 7(3 + 4); TNM stage: T2cN0M0, stage IIB) to healthy donors. The results revealed dozens of d...
Source: Clinical Proteomics - March 12, 2024 Category: Biochemistry Source Type: research
Neat plasma proteomics: getting the best out of the worst
This study explores ways to improve proteome coverage in neat plasma both in MS data acquisition and MS data analysis. We demonstrate the value of sampling smaller hydrophilic peptides, increasing chromatographic separation, and using library-free searches. Additionally, we introduce the EV boost approach, that leverages on the extracellular vesicle fraction to enhance protein identification in neat plasma samples. Globally, our optimized analysis workflow allows the quantification of over 1000 proteins in neat plasma with a 24SPD throughput. We believe that these considerations can be of help independently of the LC –MS...
Source: Clinical Proteomics - March 12, 2024 Category: Biochemistry Source Type: research
Correction to: Using phosphoproteomics data to understand cellular signaling: a comprehensive guide to bioinformatics resources
(Source: Clinical Proteomics)
Source: Clinical Proteomics - March 7, 2024 Category: Biochemistry Source Type: research
Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling
AbstractIn persons with dyslipidemia, a high residual risk of cardiovascular disease remains despite lipid lowering therapy. Current cardiovascular risk prediction mainly focuses on low-density lipoprotein cholesterol (LDL-c) levels, neglecting other contributing risk factors. Moreover, the efficacy of LDL-c lowering by statins resulting in reduced cardiovascular risk is only partially effective. Secondly, from a metrological viewpoint LDL-c falls short as a reliable measurand. Both direct and calculated LDL-c tests produce inaccurate test results at the low end under aggressive lipid lowering therapy. As LDL-c tests under...
Source: Clinical Proteomics - March 1, 2024 Category: Biochemistry Source Type: research
Proteomic analysis of plasma proteins from patients with cardiac rupture after acute myocardial infarction using TMT-based quantitative proteomics approach
ConclusionsOur study highlights the value of comprehensive proteomic characterization for identifying plasma proteome changes in patients with CR. This pilot study could serve as a valid foundation and initiation point for elucidation of the mechanisms of CR, which might aid in identifying effective diagnostic biomarkers in the future. (Source: Clinical Proteomics)
Source: Clinical Proteomics - March 1, 2024 Category: Biochemistry Source Type: research
Highly sensitive therapeutic drug monitoring of infliximab in serum by targeted mass spectrometry in comparison to ELISA data
ConclusionsIn this study, a semi-automated workflow was employed and tested with 8 patients and corresponding replicates (n = 3–4). We demonstrated the robust implementation of calibration curves for the absolute quantification of infliximab in patient samples, with coefficients of variation ranging from 0.5 to 9%. Taken together, we have developed a platform enabling the rapid (2 days of sample preparation and 30 min of measurement time per sample) and robust quantification of Infliximab antibody concentration in patients. The use of mass spectrometry also facilitates the straightforward expansion of the method to...
Source: Clinical Proteomics - February 29, 2024 Category: Biochemistry Source Type: research
Proteomic analysis of breast cancer based on immune subtypes
ConclusionsCoronin-1A and α-1-antitrypsin were upregulated in immune-inflamed and immune-excluded/desert subtypes, respectively. Titin's elevated expression in pCR within the immune-inflamed subtype may indicate a favorable prognosis. Further studies involving large representative cohorts are necessary to validate these fin dings. (Source: Clinical Proteomics)
Source: Clinical Proteomics - February 29, 2024 Category: Biochemistry Source Type: research
